PDCD1 and Miyoshi myopathy: In addition, FDA put on hold all the clinical trials using anti–PD-1/PD-L1 antibodies in combination with other therapeutic agents, as the immunomodulatory drugs (IMiDs), in MM because of severe adverse events (https://www.fda.gov/Drugs/DrugSafety/ucm574305.htm).